Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofuran SCHEMBL360933 | 0.97 | ALDH1A1 (0.50) | ALDH1A1USP2SMN1; SMN2 | |
| Tetrahydrofuran SCHEMBL28159237 | 0.94 | ALDH1A1 (0.47) | ALDH1A1USP2SMN1; SMN2 | |
| Dioxane SCHEMBL1921978 | 0.84 | ALDH1A1 (0.57) | ALDH1A1USP2SMN1; SMN2 | |
| Methoxymethane SCHEMBL9829152 | 0.81 | — | — | |
| Cyclohexane SCHEMBL357093 | 0.80 | ALDH1A1 (0.73) | ALDH1A1 | |
| SCHEMBL1921976 | 0.79 | ALDH1A1 (0.50) | ALDH1A1 | |
| Tetrahydrofuran SCHEMBL2041223 | 0.77 | — | — | |
| Chloromethane SCHEMBL27584162 | 0.77 | — | — | |
| Tetrahydrofuran SCHEMBL2514312 | 0.77 | ALDH1A1 (0.47) | ALDH1A1USP2SMN1; SMN2 | |
| Tetrahydrofuran SCHEMBL8787962 | 0.77 | ALDH1A1 (0.47) | ALDH1A1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004083180-A1 | NOVEL CRYSTALLINE FORMS OF LEVETIRACETAM | HETERO DRUGS LIMITED (IN) | 2004-09-30 | — | — | WO | claimed |
| US-8541419-B2 | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists | ACTIMIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2328876-B1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTIMIS PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | GB005, INC. | 2011-07-14 | — | — | US | disclosed |
| EP-2328876-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Actimis Pharmaceuticals, Inc., (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010027448-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTIMIS PHARMACEUTICALS INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20050143445-A1 | Novel crystalline forms of levetiracetam | HETERO DRUGS LIMITED (IN) | 2005-06-30 | — | — | US | disclosed |
| WO-2004083180-A1 | NOVEL CRYSTALLINE FORMS OF LEVETIRACETAM | HETERO DRUGS LIMITED (IN) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143445-A1 | Novel crystalline forms of levetiracetam | EPM2A, MAPT, ATG4A | ALDH1A1 2664/4885USP2 1806/4885SMN1; SMN2 4129/4885 |
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH4 | ALDH1A1 599/4885USP2 899/4885SMN1; SMN2 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.